Publications
Business Consulting
Atlantic Institute
Brave New World -- European Biopharmaceutical Review - October, 2016
Much has been discussed regarding UK's referendum to leave the EU. Changes in the economic and competitive business environment present an opportunity to identify and implement value-creating innovations. US-baased contributor Emile Bellott looks at some of the problems and choices facing biopharmaceutical enterprises in the post-Brexit era.
Less Is More -- European Biopharmaceutical Review - July , 2016
Ludwig Mies van der Rohe famously declared “Less is More ” as a precept of minimalist design. Now, as the cost continues to rise, governments, payers, and patients are calling for the global healthcare enterprise to “do more with less.” Spurred onward by new high-tech therapies for underserved medical needs, we are entering uncharted territory. These advances hold out the promise a complete cure, at unprecedented high price points, which are, nevertheless smaller than the time-weighted total cost of a lifetime of chronic therapy.
Eye of the Storm -- European Biopharmaceutical Review - April, 2016
No stranger to publicity, biosimilars are gaining visibility at the highest levels of government – including the recent Trans-Pacific Partnership and the US government’s proposed 2017 federal budget. Emile Bellott explores the ‘perfect storm’ surrounding biosimilars – along with some of the unintended consequences.
Niche Boom -- European Biopharmaceutical Review - January, 2016
Three years ago, EBR proposed eight New Year's Resolutions for the biopharma industry to help bolster pipeline productivity. Number two on the list was: "Shift focus away from blockbusters – rare diseases have proven to be highly profitable." Emile Bellott takes another look at the orphan drug situation, in light of current focus on drug pricing.
A Banner Year for BioPharma -- European Biopharmaceutical Review - October, 2015
In this special edition of In Brief, Industry Advisor Emile Bellott looks at the recent headlines, reflecting on the successes of last year and commenting on what the future holds for biopharma.
In The Lead -- European Biopharmaceutical Review - July, 2015
Biosimilars have been on the horizon for over a decade, with European and Asian markets and regulators heading the wave of innovation. In contrast, in the US, the first true biosimilar drug has only recently been approved. Emile Bellott considers the sectors’ future outlook and declares that the race is on
The Weakest Link -- European Biopharmaceutical Review - April, 2015
How can we know which patients will benefit from prescribed treatments and which will not? Emile Bellott looks at the current approaches to precision medicine and suggests how the industry can keep pace with popular expectations
Crouching Tiger -- European Biopharmaceuutical Review - January, 2015
The Chinese Pharma market is a perfect storm of growth, demographics, and under-served medical need. While major firms compete globally and establish operations in the country, Emile Bellott asks: Will China have multinational companies of its own within a decade? And how will they compete with a century of European and American dominance?
A Tale of Two Cities -- European Biopharmaceutical Review - October, 2014
As biotechnology and pharmaceutical companies face increasing scrutiny over pricing innovative drugs, Emile Bellott explores the rationale and factors impacting the valuation of new drugs from the perspectives of two cities – Washington DC and London
Follow The Money -- European Biopharmaceutical Review - April 2014
With partnering and outsourcing now integral to the biotech and pharma landscape, Emile Bellott explores the rapid rise of biomedical R&D in East Asia – and how it may affect future generations of biotech companies
The Return of the Blockbuster ? -- European Biopharmaceutical Review - January 2014
The past decade has seen a rise in the cost of developing a new drug, greater externalisation of pipelines, and a shift in strategic emphasis towards niche indications. Many industry leaders declare that the blockbuster era is over. Emile Bellott explores an alternative point of view